Tirzepatide and DVT: What the Evidence Actually Shows

Step 1: What the UK prescribing information actually records

The starting point is the licensed prescribing information, not online speculation. Tirzepatide's UK SmPC (the authoritative clinical document published on the Electronic Medicines Compendium) does not list DVT among the known or suspected side effects at any dose. The MHRA's Black Triangle designation for tirzepatide means the medicine is under additional post-marketing surveillance, but that monitoring is in place for all newer medicines, not because clotting events have been flagged as a pattern. The NHS patient information for tirzepatide, similarly, does not include blood clots in its side-effect profile. That absence reflects what the clinical trial data showed: across the SURMOUNT programme, involving thousands of adults, venous thromboembolism was not identified as an adverse event associated with the medicine itself. This page on how tirzepatide works and what it's licensed for covers the broader evidence base if you want more background, and you can also read about tirzepatide l for further detail on this formulation.

None of this means the question is unreasonable. It means the concern about DVT is most usefully framed not as 'does this drug cause clots?' but as 'what does my personal clotting history mean for whether this treatment is right for me?'

Step 2: Why obesity itself raises DVT risk, and why that matters here

Obesity is a recognised independent risk factor for deep vein thrombosis and pulmonary embolism. The mechanisms are well documented: excess adipose tissue promotes a pro-inflammatory, pro-coagulant state; reduced mobility compounds venous stasis; and abdominal pressure can impair venous return from the lower limbs. This is the population (adults living with obesity) that tirzepatide is licensed to treat. So when someone starting this medicine asks about DVT, the relevant question isn't only about the drug. It's about a person whose underlying condition already confers some elevated clotting risk, now considering a treatment that may, over months, substantially reduce that underlying condition. The detailed look at Mounjaro and DVT risk explores this interaction more fully. A prescriber reviewing your consultation considers your complete picture: weight, mobility, any prior clotting events, concurrent medicines, and whether additional precautions are warranted. That's precisely why clinical assessment exists, not as a bureaucratic hurdle, but as the step that makes treatment safer for people with complex histories. The NHS page on tirzepatide sets out the full list of known side effects and who should exercise caution.

Step 3: What to disclose, and who decides

If you have a personal or family history of DVT, pulmonary embolism, thrombophilia, or you're on anticoagulant therapy, that information should be in your consultation notes. It won't automatically exclude you from treatment, many people with a history of blood clots live with obesity and have legitimate clinical need for weight management support. But it shapes the conversation. A prescriber may want to know your current anticoagulation status, whether the DVT was provoked or unprovoked, and what mobility looks like day-to-day. If you've been exploring options already, the question of whether Mounjaro can cause DVT is addressed in detail elsewhere. For comparison of tirzepatide with other treatments from a clinical angle, the Mounjaro or tirzepatide overview may help orient you. The point is that the decision sits with a clinician who knows your history, not with a general information page, and not with an algorithm. At nume, a named GPhC-registered Independent Prescriber reads every consultation personally the same day. If this DVT question applies to your situation, you can flag it directly in your consultation notes. See how our consultation process works and speak to our prescribers if you're ready to take that step.

A note on ongoing monitoring

Tirzepatide carries the MHRA's Black Triangle status, which means any suspected adverse effects (including unexpected cardiovascular or clotting events) should be reported via the Yellow Card scheme. This isn't unique to tirzepatide: it applies to all recently authorised medicines and is part of how the UK's post-marketing surveillance catches rare signals early. If you're already on treatment and notice leg pain, swelling, redness, or warmth, seek medical attention promptly rather than waiting for your next medication review. Those are symptoms that warrant assessment regardless of what you're taking. Separately, if you're weighing up the broader question of private versus NHS access, the weight loss treatment overview covers both routes, and the Mounjaro treatment page sets out current private eligibility criteria. The clinical team behind our service is introduced on the clinical team profile if you want to know more about who reviews your notes.